Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lusutrombopag for non-severe aplastic anemia
ChiCTR2400084012Phase 4Recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lusutrombopag in aplastic anemia, sponsored by Tianjin Medical University General Hospital. Primary endpoint: Proportion of subjects with a hematologic response of at least one lineage at Week 8. Started Apr 2024; status: recruiting.
02
Drugs
lusutrombopag
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on ChiCTR2400084012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084012.